Lys97

Site Information
PRNKISFkFDHLRkE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 466097
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:	colorectal cancer ( 6 , 7 ) , colorectal carcinoma ( 6 , 7 ) , leukemia ( 4 , 5 ) , chronic myelogenous leukemia ( 4 , 5 ) , non-small cell lung cancer ( 1 , 2 ) , non-small cell squamous cell lung carcinoma ( 2 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 8 ) , HCT116 (intestinal) ( 6 , 7 , 9 ) , HCT8/S11 (intestinal) ( 10 ) , Jurkat (T lymphocyte) ( 8 ) , K562 (erythroid) ( 4 , 5 ) , MV4-11 (macrophage) ( 8 ) , NCI-H1703 (squamous) ( 2 ) , NCI-H3122 (pulmonary) ( 1 )

References
1	Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
2	Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
4	Moritz A (2010) CST Curation Set: 9922; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
5	Moritz A (2010) CST Curation Set: 9921; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
6	Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
9	Li Y (2006) CST Curation Set: 1658; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Li Y (2006) CST Curation Set: 1475; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info